UNC Vascular Surgeons Mark Farber, MD, Professor and Chief of Vascular Surgery and F. Ezequiel Parodi, MD, Associate Professor of Vascular Surgery implanted the first commercial device in a patient on Friday, May 10th, 2024.
The GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE) is an endovascular stent graft to treat complex aneurysmal disease involving the visceral aorta. This device is the first device in the US approved for this indication.
Dr. Farber was the National PI for the trial, which completed enrolment last year. (Read more by clicking on our article about this trial).
In January 2024, the FDA approved the device with commercial release planned for June of 2024. Read more here and here.